Al Duarte-Garca

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8018663/ali-duarte-garcia-publications-by-year.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47	703	13	26
papers	citations	h-index	g-index
52 ext. papers	1,187 ext. citations	6.1 avg, IF	4.28 L-index

#	Paper	IF	Citations
47	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy <i>Frontiers in Immunology</i> , 2022 , 13, 834981	8.4	3
46	Industry involvement in rheumatology consensus-based recommendations: a systematic review. <i>Lancet Rheumatology, The</i> , 2022 , 4, e145-e152	14.2	
45	Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology <i>Mayo Clinic Proceedings</i> , 2022 , 97, 250-260	6.4	Ο
44	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey <i>Lancet Rheumatology, The</i> , 2022 ,	14.2	4
43	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	5
42	Epidemiology of Antiphospholipid Syndrome in the General Population <i>Current Rheumatology Reports</i> , 2022 , 23, 85	4.9	2
41	Time to transition from psoriasis to psoriatic arthritis: A population-based study <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 52, 151949-151949	5.3	O
40	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2129639	10.4	17
39	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review And Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	20
38	Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study. <i>Arthritis Care and Research</i> , 2021 ,	4.7	2
37	Population-Based Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria. <i>Rheumatology</i> , 2021 ,	3.9	3
36	Characteristics of Hydroxychloroquine Dispensing in the United States, January to May 2020. Journal of General Internal Medicine, 2021 , 1	4	
35	75-Year-Old Man With Fever and Malaise. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2905-2910	6.4	
34	The protective effect of rheumatic disease agents in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101659	5.3	3
33	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1137-1146	2.4	49
32	28-Year-Old Man With Recurrent Vertigo, Syncope, and Progressive Memory Impairment. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1309-1314	6.4	
31	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 36-47	9.5	34

(2020-2021)

30	Striatal Encephalitis: Potential Inflammatory Vasculopathy in Systemic Lupus Erythematosus. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 48, 415-416	1	
29	28-Year-Old Woman With Chronic Kidney Disease, Fatigue, and Polyarthralgias. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 231-236	6.4	1
28	Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021 , 48, 1410-1416	4.1	6
27	The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1878-1885	9.5	7
26	Reply. Arthritis and Rheumatology, 2021 , 73, 1767-1768	9.5	
25	Industry Payments to Practicing US Rheumatologists, 2014-2019. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2138-2144	9.5	1
24	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2021 ,	4.1	3
23	Reply. Arthritis and Rheumatology, 2020 , 72, 1776	9.5	
22	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 659-666	5.1	40
21	Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 733-749	9.5	32
20	Effect of statin use on the risk of rheumatoid arthritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1348-1356	5.3	5
19	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1191-1201	5.3	13
18	Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102688	13.6	9
17	Response to: C orrespondence on Vhydroxychloroquine, COVID-19and the role of the rheumatologist by Graef by Lo. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
16	Measuring Outcomes in Axial Spondyloarthritis. Arthritis Care and Research, 2020, 72 Suppl 10, 47-71	4.7	4
15	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020 , 29, 1571-1593	2.6	27
14	Reply. Arthritis and Rheumatology, 2020 , 72, 2164-2165	9.5	
13	Disease progression of Takayasu arteritis in two patients treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e21	2.4	8

12	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 215-227	5.3	2
11	: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 734-736	2.4	32
10	Reply. Arthritis and Rheumatology, 2019 , 71, 1769-1770	9.5	
9	Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines. <i>ACR Open Rheumatology</i> , 2019 , 1, 188-193	3.5	4
8	The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1545-1552	9.5	86
7	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019 , 46, 996-1005	4.1	21
6	Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel. <i>Annals of Internal Medicine</i> , 2019 , 170, 791-792	8	6
5	Older Drugs With Limited Trial Evidence: Are They Worth the Expense?. <i>Annals of Internal Medicine</i> , 2019 , 171, 602	8	2
4	Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction. <i>PLoS ONE</i> , 2018 , 13, e0196487	3.7	12
3	The Evidence Basis for the American College of Rheumatology Practice Guidelines. <i>JAMA Internal Medicine</i> , 2018 , 178, 146-148	11.5	15
2	Antiphospholipid Syndrome: Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2317-2330	15.1	72
1	Predictors of incident proteinuria among patients with SLE. <i>Lupus Science and Medicine</i> , 2017 , 4, e00020	04.6	12